International Journal of Clinical Oncology

, Volume 23, Issue 2, pp 400–401 | Cite as

Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib

  • Ahmet Emre Eskazan
Letter to the Editor

With the advent of imatinib—the first tyrosine kinase inhibitor (TKI) used to treat chronic myeloid leukemia (CML)—managing patients with CML in the chronic phase (CML-CP) has changed dramatically. Second-generation TKIs (2GTKIs) are more potent than imatinib and can be a better option. Nilotinib and dasatinib were superior to imatinib regarding speed and depth of responses, with no significant benefit in long-term outcomes, including progression-free and overall survivals (PFS and OS) over imatinib in the frontline setting [1].

Achieving and maintaining deep molecular response (DMR) may give patients an opportunity to temporarily discontinue TKI treatment, and treatment-free remission (TFR) was investigated in several studies, first with imatinib and then with 2GTKIs (nilotinib or dasatinib) [2]. Since the probability of gaining DMR is higher with 2GTKIs than with imatinib, it seems wiser to use these more potent TKIs in patients who wish to discontinue therapy.

I read with great...


Compliance with ethical standards

Conflict of interest

AEE has received honoraria from Novartis and Bristol-Myers Squibb.


  1. 1.
    Eskazan AE, Ozmen D (2017) Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events—is better always good? Expert Rev Hematol 10(7):583–586CrossRefPubMedGoogle Scholar
  2. 2.
    Hughes TP, Ross DM (2016) Moving treatment-free remission into mainstream clinical practice in CML. Blood 128(1):17–23CrossRefPubMedGoogle Scholar
  3. 3.
    Shiseki M, Yoshida C, Takezako N et al (2017) Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy. Int J Clin Oncol. 22:972–979CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Soverini S, Hochhaus A, Nicolini FE et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208–1215CrossRefPubMedGoogle Scholar
  5. 5.
    Eskazan AE, Eyice D, Kurt EA et al (2014) Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leuk Res 38(7):781–787CrossRefPubMedGoogle Scholar
  6. 6.
    Ozgur Yurttas N, Sadri S, Keskin D et al (2015) Real-life data and a single center experience on dasatinib-induced pulmonary arterial hypertension in patients with Philadelphia chromosome-positive leukemias. Blood 126(23):4037 (Abstract) Google Scholar
  7. 7.
    Kirkizlar O, Eskazan AE (2016) Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Rev Qual Life Cancer Care 1(5):353–359CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  1. 1.Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of MedicineIstanbul UniversityIstanbulTurkey

Personalised recommendations